Martin Kulander

Präsident bei Transition Bio, Inc.

Health Technology

Aktive Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Tuomas Knowles	M	-	Transition Bio, Inc. Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles.	-
Shilpi Arora	F	-	Transition Bio, Inc. Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles.	-
George Martin	M	65	Transition Bio, Inc. Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles.	-
Peter H. St George-Hyslop	M	-	Transition Bio, Inc. Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles.	-
David A. Weitz	M	-	Transition Bio, Inc. Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles.	-
Gregory L. Miller	M	46	Transition Bio, Inc. Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles.	-
Alfred Sandrock	M	67	Transition Bio, Inc. Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles.	-
Samuel Cohen	M	38	Transition Bio, Inc. Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles.	-
Shaan Gandhi	M	38	Transition Bio, Inc. Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles.	-
Sarah Teichmann	F	-	Transition Bio, Inc. Transition Bio, Inc. BiotechnologyHealth Technology Transition Bio, Inc. is a company based in Watertown, MA that is developing technologies for biomolecular condensate analysis. The company's proprietary drug discovery platform, CondensomicsTM, utilizes droplet microfluidics and machine learning to map and modulate condensates in molecular detail. The company's goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. Transition Bio has been founded by Sarah Teichmann, David A. Weitz, Peter H. St George-Hyslop, and Tuomas Knowles.	-